Collaborative innovation in drug discovery : strategies for public and private partnerships
Author(s)
Bibliographic Information
Collaborative innovation in drug discovery : strategies for public and private partnerships
（Wiley series on technologies for the pharmaceutical industry）
Wiley, c2014
- : cloth
Available at / 2 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Can academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior Director-Discovery Sciences, SRI International, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement.
Gain global perspectives on the benefits and potential issues surrounding collaborative innovation
Discover how industries can come together to prevent another "Pharma Cliff"
Learn how nonprofits are becoming the driving force behind innovation
Read case studies of specific academia-pharma partnerships for real-life examples of successful collaboration
Explore government initiatives that help foster cooperation between industry and academia
Dr. Chaguturu's thirty-five years of experience in academia and industry, managing new lead discovery projects and forging collaborative partnerships with academia, disease foundations, nonprofits, and government agencies lend him an informative perspective into the issues facing pharmaceutical progress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and his expert team provide insight into the various nuances of the debate.
Table of Contents
- Foreword xv by Ferid Murad Preface xix About the Book xxv About the Editor xxvii Contributors xxix PART I: PERSPECTIVES ON COLLABORATIVE INNOVATION 1 If I have seen further it is by standing on the shoulders of giants. -Isaac Newton 1 PRODUCTIVE RELATIONSHIPS IN RESEARCH AND DEVELOPMENT BETWEEN GOVERNMENT, INDUSTRY, AND UNIVERSITIES 3 Wyatt R. Hume 2 DIVIDED WE FALL 11 William B. Mattes 3 INNOVATION: OPEN SOURCE AND NONPROFIT MODELS IN DRUG DISCOVERY 21 James M. Shaeffer and Sarah MacDonald 4 THE CHANGING FACE OF INNOVATION IN DRUG DISCOVERY 31 Litao Zhang and Carl Decicco 5 CURRENT TRENDS IN COLLABORATIVE DRUG DISCOVERY AND STRATEGIES TO DE-RISK PRECOMPETITIVE INITIATIVES 57 Anuradha Roy and Rathnam Chaguturu 6 A PERSPECTIVE ON THE EVOLUTION OF COLLABORATIVE DRUG DISCOVERY AND FUTURE CHALLENGES 75 Christopher A. Lipinski PART II: GOVERNMENTAL INITIATIVES ACCELERATE PRECOMPETITIVE COLLABORATION 85 Governments will always play a huge part in solving big problems. . . . They also fund basic research, which is a crucial component of the innovation that improves life for everyone. -Bill Gates 7 THE VALUE OF UNIVERSITY-INDUSTRY PARTNERSHIPS 87 Anthony M. Boccanfuso 8 TRENDS IN THE PUBLIC SECTOR ADOPTION OF TRANSLATIONAL RESEARCH APPROACHES 99 Mark A. Scheideler 9 PARTNERSHIPS FOR DRUG REPOSITIONING: LESSONS FROM THE CTSA PHARMACEUTICAL ASSETS PORTAL 115 Kate Marusina, Dean J. Welsch, Lynn Rose, Doug Brock, Nathan Bahr, Aaron M. Cohen, Rafael A. Gacel-Sinclair, Pakou Vang, Peter G. Ruminski, Bruce E. Bloom, Pamela Nagasawa, and Betty P. Guo 10 DEVELOPMENT PROGRAMS AT THE U.S. NATIONAL CANCER INSTITUTE: USE OF PUBLIC-PRIVATE PARTNERSHIPS AS A CATALYST TO ADVANCE CANCER THERAPY 135 Jason V. Cristofaro 11 NONINDUSTRIAL PHARMACEUTICAL RESEARCH IN THE BRIC COUNTRIES: LESSONS FOR DRUG DISCOVERY PARTNERSHIPS WITH ACADEMIC AND GOVERNMENTAL INSTITUTIONS 159 John Watson 12 DEATH OF DRUGS AND REBIRTH OF HEALTH CARE: INDIAN RESPONSE TO DISCOVERY IMPASSE 173 Bhushan Patwardhan PART III: A GAME CHANGER FOR AVERTING FUTURE PHARMA CLIFF 195 Coming together is a beginning, staying together is progress, and working together is success. -Henry Ford 13 ACCELERATING INNOVATION IN THE BIOSCIENCE REVOLUTION 197 Bernard H. Munos 14 VALUE-DRIVEN DRUG DEVELOPMENT: UNLOCKING THE VALUE OF YOUR PIPELINE 213 Valentina Sartori, Michael Steinmann, Petra Jantzer, and Matthias Evers 15 UNLOCKING THE MARKET POTENTIAL OF ACADEMIC RESEARCH 221 Assem S. el Baghdady and Yasser M.S. el Baghdady 16 COLLABORATIVE INNOVATION IN PHARMACEUTICAL INDUSTRY: APPROACHES AND REQUIREMENTS 255 Monika Lessl and Khusru Asadullah 17 CLOSE CONTACT: A COLOCATION MODEL FOR ACADEMIC-INDUSTRIAL PARTNERSHIPS IN DRUG DISCOVERY 267 Peter A. Covitz and Terrence D. Ruddy 18 SUCCESS FACTORS AND OBSTACLES IN ACADEMIA-INDUSTRY PARTNERSHIPS: A CASE STUDY OF A GRADUATE PROGRAM WITHIN THE BAYER-UNIVERSITY OF COLOGNE "PRIVILEGED PARTNERSHIP" 279 Stefan Herzig, Marion Rozowski, and Ingo Flamme 19 ACADEMIC, COMMERCIAL, AND BIODEFENSE CASE STUDIES FOR COLLABORATIVE DRUG DISCOVERY: POTENTIAL FOR DISRUPTING DRUG DISCOVERY 303 Barry A. Bunin and Sean Ekins 20 ACCESS PLATFORM: A STREAMLINED INTEGRATIVE PARTNERING PROCESS AT SANOFI TO COMMERCIALIZE UNIVERSITY-BASED INTELLECTUAL PROPERTY 319 Paul R. Eynott and Carole Fages 21 ENTREPRENEURSHIP: DRUG DISCOVERY INNOVATION AT START-UP AND MEDIUM-SIZED BIOTECHNOLOGY COMPANIES 341 Allen B. Reitz and Kathleen M. Czupich 22 CHEMICAL CONSULTING 355 Lester A. Mitscher PART IV: NONPROFITS DRIVE BENCH-TO-BEDSIDE INNOVATION 367 Can't afford to innovate? Open up! -Henry Chesbrough 23 OPEN SOURCE DRUG DISCOVERY FOR NEGLECTED DISEASES 369 Tonny Johnson and Sanchayita Kar 24 THE MYELIN REPAIR FOUNDATION ACCELERATED RESEARCH COLLABORATIONTM MODEL: INNOVATIVE DISRUPTION IN BIOMEDICAL RESEARCH 385 Gali Hagel 25 FROM CATALYSIS TO MASS ACTION: THE EVOLUTION OF CHDI FOUNDATION, A DRUG-DEVELOPMENT ORGANIZATION DEVOTED TO HUNTINGTON'S DISEASE 411 Allan J. Tobin 26 LESSONS FROM THE PAST AS A MEANS TO THE FUTURE: INSTITUT PASTEUR AS A MODEL STRATEGY 437 Spencer L. Shorte 27 SEEDING OPEN INNOVATION DRUG DISCOVERY AND TRANSLATIONAL COLLABORATIONS TO LEVERAGE GOVERNMENT FUNDING: A CASE STUDY OF STRATEGIC PARTNERSHIP BETWEEN SANFORD-BURNHAM AND MAYO CLINIC 451 Thomas D.Y. Chung, Sundeep Khosla, Andrew D. Badley, and Michael R. Jackson PART V: ACADEMIC SCREENING CENTERS COME OF AGE 487 Open access high-throughput drug discovery in the public domain is a Mount Everest in the making. -Rathnam Chaguturu 28 FINDING THE MIDDLE GROUND: DRUG DISCOVERY TECHNOLOGY IN THE ERA OF ACADEMIC SCREENING CENTERS 489 Nathan S. Blow 29 OPEN INNOVATION-BASED DRUG DISCOVERY IN EUROPE: SOME EXAMPLES OF NATIONAL AND TRANSNATIONAL EUROPEAN INITIATIVES INTEGRATING CHEMISTRY, BIOLOGY, AND TECHNOLOGY PLATFORMS 499 Philip Gribbon 30 IN SICKNESS AND IN HEALTH: A SHOTGUN MARRIAGE THAT IS FLOURISHING 517 Horst Flotow and Alex Matter 31 A FLEXIBLE MODEL FOR COMPOUND MANAGEMENT FACILITIES TO STIMULATE COLLABORATIONS IN THE LIFE SCIENCES 533 David Camp PART VI: INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER 563 Everything that can be invented has been invented. -Charles Duell 32 SUCCESSFUL TECHNOLOGY TRANSFER: LESSONS FROM THE TRANSLATIONAL MEDICINE RESEARCH COLLABORATION 565 Assem S. el Baghdady 33 CHALLENGES AND OPPORTUNITIES IN COMMERCIALIZING ACADEMIC DRUG DISCOVERIES 577 Christopher Paschall 34 THE PIVOTAL ROLE OF THE ACADEMIC ENTREPRENEUR AND THE ENTREPRENEURIAL UNIVERSITY IN GLOBAL LIFE SCIENCES 609 Donna Marie De Carolis PART VII: THE FINAL FRONTIER 621 No one can whistle a symphony
- it takes a whole orchestra to play it. -Halford E. Luccock 35 THE CORE MODEL: DRUG DISCOVERY AND DEVELOPMENT VIA EFFECTIVE TRANSLATIONAL SCIENCE AND PUBLIC-PRIVATE COLLABORATION 623 Ibis Sanchez-Serrano 36 USING MARKET-DRIVEN COLLABORATION TO ACCELERATE INNOVATION IN BIOMEDICINE 653 Elizabeth Iorns 37 THE COST OF TAKING EYES OFF THE TRUE END USER: FOCUS ON PATIENT NEEDS AND OUTCOMES 663 Deborah E. Collyar 38 TO LEASH OR UNLEASH THE POWER OF PUBLIC-PRIVATE COLLABORATION: IN HEALTH AND DISEASE 679 Hakim Djaballah Index 687
by "Nielsen BookData"